XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
The reference standard transfer is the analytical foundation on which everything else in a technology transfer stands. When the receiving site tests the transferred process validation batches, the stability samples, or the first commercial
View details →
When you transfer your manufacturing process into a multi-product CMO, cleaning validation stops being the CMO's general housekeeping practice and becomes a regulatory control specific to your API. The question FDA investigators ask during
View details → Selecting a CMO and signing the manufacturing agreement is not the beginning of the regulatory pathway to an approved manufacturing site — it is the business step that precedes the regulatory program. The regulatory
View details → The CMO technical agreement is the last place most CMC teams look when a manufacturing crisis hits — and the first place they should have looked when the agreement was being negotiated. When a
View details →
Supply chain redundancy is the supply chain strategy. Dual-source manufacturing is the regulatory program that makes supply chain redundancy work. The difference matters because the second source cannot supply commercial product until it is
View details → An FDA-approved NDA is not a J-NDA CMC package. The ICH CTD format is common. The regulatory expectations are not.
View details → Health Canada operates under the same ICH CTD framework and uses the same ICH guideline set as FDA. None of that means a Health Canada CTA CMC package is the same as an FDA
View details → The ICH CTD format harmonized the structure of global drug regulatory submissions. It did not harmonize what goes inside them.
View details → The EMA CHMP centralized procedure has a 210-day review clock, but it has never taken 210 days for an applicant to discover what a Major Objection on quality looks like.
View details → ICH Q8, Q9, and Q10 represent the most successful pharmaceutical regulatory harmonization initiative in history — and also one of the most consistently misunderstood.
View details → TCR-T therapy teams that inherit the CAR-T CMC framework inherit the wrong starting point. CAR-T identity and potency assays are built around antigen recognition that is independent of HLA — the CAR binds surface
View details → The argument for gamma-delta T cell therapy is compelling: γδ T cells kill tumors without HLA matching, can be manufactured from allogeneic donors at scale, and circumvent the MHC-restriction barrier that limits αβ T
View details → TIL therapy has achieved a regulatory milestone that few believed possible a decade ago — an FDA-approved autologous cell therapy with a manufacturing process that starts from a patient's resected tumor, requires weeks of
View details → Natural killer cell therapy offers the immunological logic for an off-the-shelf allogeneic product: NK cells kill HLA-mismatched targets through activating receptor engagement rather than antigen-specific TCR recognition, eliminating the alloreactivity risk that limits allogeneic
View details → HPMC hydrophilic matrix tablets are the most common controlled release platform in oral solid dosage form development — and the most commonly documented without the scientific argument that FDA chemistry reviewers need to evaluate
View details → For a 5 mg tablet where the API is 2.5% of the tablet weight, blend uniformity is not a process control — it is the single most consequential CQA in the manufacturing process. A
View details → A specification table in 3.2.P.5 is not a list of limits — it is a collection of regulatory arguments, each of which must be defended by data. When FDA chemistry reviewers ask "what is
View details → Selecting a container closure system for an oral solid dosage form is a stability decision, not a packaging decision. For a moisture-sensitive tablet where degradation accelerates sharply with humidity, ordinary bottle-level moisture ingress over
View details →